OpGen, Inc.
505 South Rosa Road
Suite 151
Madison
Wisconsin
53719
United States
Tel: 608-441-8100
Website: http://www.opgen.com/
198 articles about OpGen, Inc.
-
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
11/14/2023
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
-
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
10/12/2023
OpGen, Inc. announced that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash, wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share.
-
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
8/10/2023
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
-
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
8/7/2023
OpGen, Inc. announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.
-
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
8/3/2023
OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has signed an extended and continued research and development collaboration agreement with FIND.
-
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
8/3/2023
OpGen, Inc. announced that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023.
-
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
7/19/2023
OpGen, Inc. reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND.
-
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
6/26/2023
OpGen, Inc. and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.
-
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
6/22/2023
OpGen, Inc. reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany.
-
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
6/20/2023
OpGen, Inc. reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe’s In Depth Symposium session ‘The Year in Clinical Microbiology’ on June 17th in Houston, TX.
-
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
5/15/2023
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2023 financial and operating results.
-
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
5/8/2023
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th , 2023.
-
OpGen Announces Closing of $3.5 Million Public Offering
5/4/2023
OpGen, Inc. announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share and accompanying warrant.
-
OpGen Announces Pricing of $3.5 Million Public Offering
5/1/2023
OpGen, Inc. today announced the pricing of a public offering of an aggregate of 4,495,825 shares of its common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share (or pre-funded warrant in lieu thereof) and accompanying warrant.
-
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
4/26/2023
OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development collaboration agreement with FIND.
-
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
4/18/2023
OpGen, Inc. today announced that it has submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for its Unyvero UTI Urinary Tract Infection (UTI) panel, following successful completion of its clinical trial.
-
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
4/18/2023
OpGen, Inc. announced that the Company has entered into a non-exclusive distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific.
-
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
4/5/2023
OpGen, Inc. reported that it signed an amendment to its research and development collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.
-
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
4/3/2023
OpGen, Inc. reported that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant.
-
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/29/2023
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2022 and full-year 2022 financial and operating results and provided a business update.